Trending...
- Awake! Ye Sisters All: Sisterhood in Boston's Women's Voter Registers
- Boston: Inaugural Cohort of Young Black Leaders Announced
- See what our March partners are offering now!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on January 11, 2023, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an aggregate of 13,500 shares of its common stock to five new employees, consisting of stock options to purchase an aggregate of 9,000 shares of common stock and restricted stock units ("RSUs"), covering an aggregate of 4,500 shares of its common stock.
These stock options and inducement RSUs are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the "Inducement Plan").
The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to their entering into employment with Seres pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan was adopted by Seres' board of directors in December 2022.
The stock options have an exercise price of $5.26 per share. Each option will vest as to 25% of the total number of shares subject to the option on the first anniversary of the applicable individual's date of hire and as to 6.25% of the total number of shares subject to the option upon a completion of each three full months of service to the Company thereafter. The RSUs vest as to 25% of an award on the first 15th day of a calendar month that immediately follows the first anniversary of the applicable individual's date of hire and as to an additional 6.25% of the award, upon completion of each three full months of service to the Company thereafter.
More on Boston Chron
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. For more information, please visit www.serestherapeutics.com.
Contacts
PR
Kristin Ainsworth
kainsworth@serestherapeutics.com
IR
Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com
These stock options and inducement RSUs are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the "Inducement Plan").
The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to their entering into employment with Seres pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan was adopted by Seres' board of directors in December 2022.
The stock options have an exercise price of $5.26 per share. Each option will vest as to 25% of the total number of shares subject to the option on the first anniversary of the applicable individual's date of hire and as to 6.25% of the total number of shares subject to the option upon a completion of each three full months of service to the Company thereafter. The RSUs vest as to 25% of an award on the first 15th day of a calendar month that immediately follows the first anniversary of the applicable individual's date of hire and as to an additional 6.25% of the award, upon completion of each three full months of service to the Company thereafter.
More on Boston Chron
- Boston: March 2023: Latest Updates from the Mayor's Office of Housing
- Boston: April Allston/Brighton Community Center Study Meeting
- Boston: Mayor Wu Launches $750,000 Grant Fund to Support Growth of Businesses and Access to City Contracts
- Mayor Wu Announces $4 Million Investment to Expand Boston's Tuition Free Community College Program
- Boston: Meet the Fine Arts Work Center Scholarship Recipients
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. For more information, please visit www.serestherapeutics.com.
Contacts
PR
Kristin Ainsworth
kainsworth@serestherapeutics.com
IR
Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com
Filed Under: Business
0 Comments
Latest on Boston Chron
- Boston: Ramadan Mubarak! City Council extends best wishes to Muslims
- Boston: Council Adopts Resolution to Improve Quality of Life for D7
- American University of Antigua announces its participation in the Consortium of Universities for Global Health 2023 Annual Conference
- Geostrategy.rs: The End of Free Media Era
- Introducing inSIGHT Mobile Machine Displays
- Local Real Estate Broker Offers Homeowners Cash Offer at Full Market Value with No Inspection Needed
- MaGO PR to Lead Specialized Public Relations Campaigns for the Presidio Trust
- Shima Capital's Founder Yida Gao Teaches Crypto Finance Course at MIT
- Max Amini Announces Powerful Interview with Reza Pahlavi, Former Crown Prince of Iran; to Premiere April 1st
- Independent Retirement and Investment Specialists Johnson Brunetti Expand to South Shore
- The South Shore Chamber of Commerce and NE Real Estate Journal Name Speakers for Summit
- Veterans For Trump aka VFAF: Trump Bus rolls into Georgia Ron DeSantis event overshadowing Tiny Desantis box truck at Veterans for Trump mini-rally
- Palos Verdes Real Estate Agent Promotes Homes To MORE Opportune Buyers For Significantly MORE Money
- Access Control Systems Expands and Rebrands as Guardian Access Solutions as Part of Increased Service Offerings
- Peachtree Immediate Care Opens Urgent Care Clinic in Marietta
- Olga Torres Named Top Advisor by Foreign Investment Watch
- Benchmark International Scsflly Fclitd The Trnstn Btw Bagel King Wholesale and Austin Circle Partner
- Attorney Steve Hilst Named Partner at Bisnar Chase
- 26 Provider Fairview Community Health Center Transitions to Intelligent eClinicalWorks Cloud
- New xBit Digital Case Management Feature Saves Examiners Hours of Required Report Upload Time